How Third Quarter Results At Personalis (PSNL) Have Changed Its Investment Story

Simply Wall St.11-07

Personalis reported third quarter 2026 revenue of US$25.6 million, compared with US$14.5 million a year earlier, alongside a net loss of US$33.8 million versus US$21.65 million and basic and diluted ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681896596?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","is_english":true,"pubTime":"2026-11-07 01:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681896596","market":"hk","top_or_hot":-1,"title":"How Third Quarter Results At Personalis (PSNL) Have Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Personalis reported third quarter 2026 revenue of US$25.6 million, compared with US$14.5 million a year earlier, alongside a net loss of US$33.8 million versus US$21.65 million and basic and diluted ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-third-quarter-results-at-personalis-psnl-have-changed-it\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Third Quarter Results At Personalis (PSNL) Have Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Third Quarter Results At Personalis (PSNL) Have Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 01:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-third-quarter-results-at-personalis-psnl-have-changed-it><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Personalis reported third quarter 2026 revenue of US$25.6 million, compared with US$14.5 million a year earlier, alongside a net loss of US$33.8 million versus US$21.65 million and basic and diluted ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-third-quarter-results-at-personalis-psnl-have-changed-it\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-third-quarter-results-at-personalis-psnl-have-changed-it","article_id":"2681896596","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-third-quarter-results-at-personalis-psnl-have-changed-it","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681896596","pubTimestamp":1793985703,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 6, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","PSNL":"Personalis"},"translate_title":"Personalis (PSNL) 第三季度业绩如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1.5},"content_text":"Personalis reported third quarter 2026 revenue of US$25.6 million, compared with US$14.5 million a year earlier, alongside a net loss of US$33.8 million versus US$21.65 million and basic and diluted loss per share of US$0.32 compared with US$0.24. Across the first nine months of 2026, Personalis delivered US$63.43 million in sales, compared with US$52.3 million last year, yet the cumulative net loss widened to US$95.52 million, with loss per share from continuing operations at US$0.90 compared with US$0.65. We will now look at how Personalis' wider quarterly net loss shapes the investment narrative investors have been using up to now.  Spot check Personalis against a curated 34 healthcare AI stocks that could be moving on similar earnings and cash burn stories.\nAdvertisementPersonalis Investment Narrative Recap To hold Personalis, you need to believe the MRD testing and broader oncology platform can eventually support a business with healthier gross margins and more disciplined cash use. The third quarter result, with US$25.6 million in revenue but a loss of US$33.8 million, keeps the focus on how quickly the cost base can be aligned with that opportunity. In the near term, the key swing factor is whether rising NeXT Personal volumes and expanding coverage turn into higher quality revenue that narrows losses. The biggest risk is that current cash burn and a widening nine month loss of US$95.52 million extend longer than expected, which can pressure the balance sheet and shareholder dilution. The most relevant development tied to this update is management’s earlier indication that 2026 cash usage could be around US$100 million and the guided net loss of about US$105 million. The latest quarterly figures, with losses growing faster than sales, sit squarely in that context and keep execution on expense control in sharp focus for Personalis. For catalysts, investors are still watching adoption of NeXT Personal and the mix shift into MRD focused biopharma work. Analysts expect these factors to support faster revenue expansion. The third quarter outcome does not change those operational levers, but it underlines that progress on reimbursement, margins and any eventual Tempus integration will need to show up clearly in future quarters to ease concern around ongoing operating losses. What The Long Range Personalis Forecast Implies On current analyst assumptions, Personalis is modeled to lift revenue by 33.4% a year over the next few years, with earnings moving from a loss of US$107.2 million today to a projected profit of US$26.8 million by 2029. That shift implies an earnings swing of about US$134 million. To align with this view, forecasts point to 2029 revenue of US$165.2 million and use that same year as the anchor for long range estimates. Uncover why Personalis' fair value is essentially in line with its current price. NasdaqGM:PSNL 1-Year Stock Price Chart Exploring Other Perspectives One alternate view around Personalis leans heavily on gross margin pressure rather than MRD volume growth. The most cautious analysts were already baking in 35.0% annual revenue growth to about US$171.2 million and earnings of roughly US$27.3 million by 2029, yet still landed on a lower price target. That gap shows how sharply opinions can diverge, so treat this earnings update as a prompt to compare several narratives before deciding what feels reasonable to you. Explore another Personalis fair value estimate, including one that suggests it could be worth just $15.17. Reach Your Own Conclusion Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Personalis research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. See our latest analysis for Personalis. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Personalis' overall financial health at a glance.  Looking For More Ideas Beyond Personalis? If the Personalis story has you thinking about position sizing, cash burn and balance sheet strength, it can help to line it up against other opportunities with different risk profiles. Use the Simply Wall St Screener to compare businesses on the traits that matter most to you instead of relying on a single headline result.  For investors who want potential mispricings backed by fundamentals, start with a 42 high quality undervalued stocks that may align better with your risk and return expectations. If capital preservation and stability sit higher on your list, filter for a 32 resilient stocks with low risk scores and see which companies look steadier than the broader market. When you care most about financial resilience through the cycle, focus on a list of solid balance sheet and fundamentals (24 results) that can help you compare leverage, liquidity and overall strength side by side.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681896596","isCrawlerRequest":true}